Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Strategies to Enhance Drug Permeability across Biological Barriers / / Jingyuan Wen, Yuan Huang, editors
| Strategies to Enhance Drug Permeability across Biological Barriers / / Jingyuan Wen, Yuan Huang, editors |
| Pubbl/distr/stampa | Basel : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2023 |
| Descrizione fisica | 1 online resource (278 pages) |
| Disciplina | 338.476151 |
| Soggetto topico | Pharmaceutical industry |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910729785603321 |
| Basel : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / / Edited by Veysel Kayser
| Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / / Edited by Veysel Kayser |
| Pubbl/distr/stampa | Basel : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2022 |
| Descrizione fisica | 1 online resource (298 pages) |
| Disciplina | 338.476151 |
| Soggetto topico | Pharmaceutical industry |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910674028403321 |
| Basel : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Value creation in the pharmaceutical industry : the critical path to innovation / / edited by Alexander Schuhmacher, Markus Hinder and Oliver Gassmann
| Value creation in the pharmaceutical industry : the critical path to innovation / / edited by Alexander Schuhmacher, Markus Hinder and Oliver Gassmann |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley, , 2016 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 338.476151 |
| Soggetto topico |
Pharmaceutical industry - Technological innovations
Pharmaceutical industry |
| ISBN |
3-527-69343-2
3-527-69340-8 3-527-69341-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Related Titles; Title Page; Copyright; Table of Contents; List of Contributors; Foreword; Chapter 1: Introduction to the Book; Reference; Chapter 2: Global Epidemiological Developments; 2.1 Introduction; 2.2 Model of Epidemiological Transition; 2.3 Global Burden of Diseases; 2.4 Infectious Diseases; 2.5 Noncommunicable Diseases; 2.6 Antimicrobial Resistance; 2.7 Dynamics; References; Chapter 3: The Value of Pharmaceutical Innovation: Concepts and Assessment; 3.1 Introduction; 3.2 Concepts and Definitions of Value; 3.3 Stakeholder's Perspectives on Value
3.4 Recent Developments Influencing the Definition and Assessment of Value3.5 Recommendations: Implications for R&D; 3.6 Discussion; 3.7 Conclusion; References; Chapter 4: A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities; 4.1 Introduction; 4.2 The Historical Perspective; 4.3 The R&D Phase Model; 4.4 The Low R&D Success Rates; 4.5 The Long R&D Time Intervals; 4.6 The High Cost of Pharmaceutical R&D; 4.7 The Reduced R&D Efficiency; 4.8 Can an Increase in R&D Value Compensate the Reduced R&D Efficiency?; References; Chapter 5: Financing Pharmaceutical Innovation 5.1 Introduction5.2 Measuring Innovation: Categories of New Drugs; 5.3 Productivity of Pharmaceutical Industry throughout Time; 5.4 Measuring the Cost of Developing New Medicines; 5.5 Funding Drug Development: a Global Endeavor; 5.6 Public and Private Funds: Complementary Finance for Drug Development; 5.7 How Commercial Drug Development Projects Are Financed Today: Big Firms, Small Firms, and Their Cooperation; 5.8 Public Health Economics and Financing Pharmaceutical Innovation; 5.9 Conclusion; Acknowledgment; References; Chapter 6: Challenges and Options for Drug Discovery; 6.1 Introduction 6.2 Paradigm Shifts of R&D Organizations6.3 Productivity of Drug Discovery; 6.4 Is There an Innovation Gap in Biomedical Research?; 6.5 Why Did Drug Candidates Fail?; 6.6 Implications from the "Lessons Learnt" for Future Drug Discovery Research; Acknowledgment; References; Chapter 7: Translational Medicine: Enabling the Proof of Concepts; 7.1 Introduction; 7.2 Translational Medicine and Its Role/Value in Early Development; 7.3 Knowledge Generation; 7.4 Types of Data, Experiments, and Tools Needed to Move from Basic Research to Early Clinical Development; 7.5 FIM (Dose Escalation and MTD) 7.6 Proof of Concept (PoC)7.7 Summary; References; Chapter 8: Preclinical Safety and Risk Assessment; 8.1 Introduction; 8.2 Test Systems; 8.3 Case Study: hERG Assay; 8.4 The Preclinical "Package" during the Development of an NME; 8.5 Factors Influencing the Preclinical Data Set; 8.6 Translation into Humans: The "Therapeutic Window"; 8.7 Influence of Intended Therapeutic Use on the Risk Assessment (RA); 8.8 Deep Dive Case Study: Safety Assessment of Biological Drug Formats; 8.9 NBE Case Study 1; 8.10 NBE Case Study 2; 8.11 Carcinogenicity Risk Assessment for Marketed Drugs 8.12 Treatment Duration |
| Record Nr. | UNINA-9910137483503321 |
| Weinheim, Germany : , : Wiley, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Value creation in the pharmaceutical industry : the critical path to innovation / / edited by Alexander Schuhmacher, Markus Hinder and Oliver Gassmann
| Value creation in the pharmaceutical industry : the critical path to innovation / / edited by Alexander Schuhmacher, Markus Hinder and Oliver Gassmann |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley, , 2016 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 338.476151 |
| Soggetto topico |
Pharmaceutical industry - Technological innovations
Pharmaceutical industry |
| ISBN |
3-527-69343-2
3-527-69340-8 3-527-69341-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Related Titles; Title Page; Copyright; Table of Contents; List of Contributors; Foreword; Chapter 1: Introduction to the Book; Reference; Chapter 2: Global Epidemiological Developments; 2.1 Introduction; 2.2 Model of Epidemiological Transition; 2.3 Global Burden of Diseases; 2.4 Infectious Diseases; 2.5 Noncommunicable Diseases; 2.6 Antimicrobial Resistance; 2.7 Dynamics; References; Chapter 3: The Value of Pharmaceutical Innovation: Concepts and Assessment; 3.1 Introduction; 3.2 Concepts and Definitions of Value; 3.3 Stakeholder's Perspectives on Value
3.4 Recent Developments Influencing the Definition and Assessment of Value3.5 Recommendations: Implications for R&D; 3.6 Discussion; 3.7 Conclusion; References; Chapter 4: A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities; 4.1 Introduction; 4.2 The Historical Perspective; 4.3 The R&D Phase Model; 4.4 The Low R&D Success Rates; 4.5 The Long R&D Time Intervals; 4.6 The High Cost of Pharmaceutical R&D; 4.7 The Reduced R&D Efficiency; 4.8 Can an Increase in R&D Value Compensate the Reduced R&D Efficiency?; References; Chapter 5: Financing Pharmaceutical Innovation 5.1 Introduction5.2 Measuring Innovation: Categories of New Drugs; 5.3 Productivity of Pharmaceutical Industry throughout Time; 5.4 Measuring the Cost of Developing New Medicines; 5.5 Funding Drug Development: a Global Endeavor; 5.6 Public and Private Funds: Complementary Finance for Drug Development; 5.7 How Commercial Drug Development Projects Are Financed Today: Big Firms, Small Firms, and Their Cooperation; 5.8 Public Health Economics and Financing Pharmaceutical Innovation; 5.9 Conclusion; Acknowledgment; References; Chapter 6: Challenges and Options for Drug Discovery; 6.1 Introduction 6.2 Paradigm Shifts of R&D Organizations6.3 Productivity of Drug Discovery; 6.4 Is There an Innovation Gap in Biomedical Research?; 6.5 Why Did Drug Candidates Fail?; 6.6 Implications from the "Lessons Learnt" for Future Drug Discovery Research; Acknowledgment; References; Chapter 7: Translational Medicine: Enabling the Proof of Concepts; 7.1 Introduction; 7.2 Translational Medicine and Its Role/Value in Early Development; 7.3 Knowledge Generation; 7.4 Types of Data, Experiments, and Tools Needed to Move from Basic Research to Early Clinical Development; 7.5 FIM (Dose Escalation and MTD) 7.6 Proof of Concept (PoC)7.7 Summary; References; Chapter 8: Preclinical Safety and Risk Assessment; 8.1 Introduction; 8.2 Test Systems; 8.3 Case Study: hERG Assay; 8.4 The Preclinical "Package" during the Development of an NME; 8.5 Factors Influencing the Preclinical Data Set; 8.6 Translation into Humans: The "Therapeutic Window"; 8.7 Influence of Intended Therapeutic Use on the Risk Assessment (RA); 8.8 Deep Dive Case Study: Safety Assessment of Biological Drug Formats; 8.9 NBE Case Study 1; 8.10 NBE Case Study 2; 8.11 Carcinogenicity Risk Assessment for Marketed Drugs 8.12 Treatment Duration |
| Record Nr. | UNINA-9910817156403321 |
| Weinheim, Germany : , : Wiley, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
XBRL and strategic information : Exploting XBRL in BSC modeling / Federica Doni, Iacopo E. Inghirami
| XBRL and strategic information : Exploting XBRL in BSC modeling / Federica Doni, Iacopo E. Inghirami |
| Autore | DONI, Federico |
| Pubbl/distr/stampa | Milano : Giuffrè, 2011 |
| Descrizione fisica | 46 p. ; 24 cm |
| Disciplina | 338.476151 |
| Altri autori (Persone) | INGHIRAMI, Iacopo E. |
| Collana | Series of paper |
| Soggetto topico | Informazione economico-finanziaria - Impiego [di] Internet |
| ISBN | 88-14-15685-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-990003669080203316 |
DONI, Federico
|
||
| Milano : Giuffrè, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
